 |
Indication & Dosage |
| |
| |
| Oral |
| TREATMENT OF DEPRESSION |
| Adult:
75-100 mg daily in 3-4 divided doses, increased gradually up to max 150 mg daily in patients with severe depression. |
| |
| Oral |
| TREATMENT OF DEPRESSION |
| Child:
Adolescent: 30-50 mg daily in divided doses.
Elderly: 30-50 mg daily in divided doses. |
| |
| Oral |
| NOCTURNAL ENURESIS |
| Adult:
6-7 yr (20-25 kg): 10 mg; 8-11 yr (25-35kg): 10-20 mg; >11 yr (35-54 kg): 25-35 mg. All doses are given 30 minutes before bedtime and treatment is continued for not >3 mth. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Elderly; hepatic or renal dysfunction; benign prostatic hypertrophy; angle closure glaucoma; phaeochromocytoma; CVS disease; epilepsy; history of bowel obstruction; withdraw gradually; monitor for suicidal tendencies during early treatment; DM; thyroid disease; psychoses (may aggravate psychotic symptoms); urinary retention. Pregnancy, lactation. |
| |
|
Potentially Life-threatening
Adverse Drug Reactions |
Tachycardia, slows conduction and prolongation of PR interval, lowers seizure threshold, peripheral neuropathy, dry mouth, constipation, urinary hesitancy, confusion and blurred vision, nausea, sweating, tremor, rashes, hypersensitivity reactions, hypomania or mania, headache, hyponatraemia, abnormal LFT, endocrine disorders, movement disorders, taste disturbances. |
| |
|
| Adverse Drug Reactions |
Rare, blood dyscrasias. |
| |
|
| Interactions |
Severe hyperpyretic reaction with MAOIs, should not be used concomitantly or within 2 wk of stopping MAOIs. Potentiates hypertensive effect of sympathomimetics and anticoagulant action of coumarins. May antagonise hypotensive effects of guanethidine and similar compounds, clonidine and rauwolfia alkaloids. May cause additive CNS depression with CNS depressants (e.g. opioids, alcohol, sedatives and hypnotics). Possible increased risk of seizure with tramadol. Nortriptyline concentrations may be increased by quinidine, phenothiazines, haloperidol, inhibitors of CYP3A4, cimetidine, methylphenidate. Concentrations may be decreased by inducers of CYP3A4. Increased toxicity with SSRIs (reduce concentration). |
| |
|
|
|
